UK markets closed

CytRx Corporation (CYTR)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.5551-0.0019 (-0.34%)
At close: 3:36PM EDT
Sign in to post a message.
  • O
    Oblio
    Can anyone tell me why Zombie, who should be in jail, continues to collect over $1M in annual compensation??? This company is pretty much a shell. 4 full time employees consisting of over paid C-suite employees who basically do nothing. If their intellectual properties are worth anything near what Zombie touts why haven't they been bought out by either Orphazyme or NantQuest???
  • C
    CoolCarlos
    I know this stock and the stock market like the back of my hand I’m the most weathered professional there is.
  • O
    Oblio
    Nice job Zombie burying the most important part in today's PR. Some things never change.

    "Orphazyme’s disclosure notes that the filing communication constitutes preliminary notice from the FDA of potential review issues as part of its ordinary course review of the NDA and is not necessarily indicative of deficiencies that may be identified during the review. Orphazyme has stated that it intends to discuss the filing communication with the FDA."
  • C
    CoolCarlos
    Mark my words within 3 months 100% gains put that in the bank
  • K
    Knownow
    According to Pietro over on the ORPH Yahoo Message Board...Cytrx even a better buy now at .58??

    Pietro 4 months ago
    Cytrx stock is currently just above $0.70 for a market cap of approx. $23 million USD. Orphazyme will sell his treatment to NPC patients for 300+k USD per year and has a pool of 3000 patients world wide. If Orphazyme grabs 1500 patients for the treatment with a treatment cost of 400k USD then the sales are 600 million USD per year. Cytrx has single digit royalties on Arimoclomol in non ALS indication. Take 5% of royalties on those sales, you get 30 million USD income for Cytrx every year just from NPC indication. Such an income with the 250 million tax losses they have, brings the market cap. of Cytrx at 600 million USD - factor 30 from the current sp -> target just for NPC income $21 pps.
  • L
    L
    So they claimed that they’re ready to deliver tremendous long term value to shareholders but want to keep all the future cash ? For a company that has no pipeline and its only existence is to collect milestones and royalties. What’s good for shareholders with no dividend ? It’s only to enrich themselves with hefty salaries and bonuses.
  • G
    Greenberg
    CYTRX´s Arimoclomol partner Orphazyme with update out today ...CYTR likely getting bought soon by their partner . Bought more today i like it here very much trading almost at cash level .

    Subsequent Events

    Completed rolling submission of NDA for arimoclomol with U.S. FDA in NPC
    Announced confidential submission of draft registration statement for a potential registered public offering of American Depositary Shares in the United States
    Announced collaboration with The Michael J. Fox Foundation on Parkinson’s disease research, joining its Research Tools Consortium which brings together experts from the medical community and industry to identify and develop new tools to address unmet research needs in Parkinson’s disease

    “During the first half of the year, we made significant progress in our efforts to bring our first product candidate to market and in July completed the submission of a rolling New Drug Application (NDA) to the FDA for arimoclomol to NPC. We are pleased to be able to already provide patients in the U.S. access to this much needed treatment for NPC through an Early Access Program, which we initiated during Q1. We continue to work at pace in building a highly specialized commercial organization in anticipation of potential approval in NPC in the U.S. and in preparing to submit a marketing application for NPC to regulatory authorities in Europe during the second half of this year”, said Kim Stratton, Chief Executive Officer of Orphazyme. “Our belief that arimoclomol has pipeline-in-a-product potential was also further underlined during the first half of this year with the phase 2 data readout supporting further studies in Gaucher disease and the award by the U.S. regulators of Fast-Track Designation for arimoclomol for the treatment of ALS. Also importantly, the first half of this year saw a boost to our efforts in building a strong international biopharmaceutical company that can maximize the value of arimoclomol, with a successful private placement raising gross proceeds of DKK 745 million (~USD 110 million). We believe the next twelve months hold significant potential for Orphazyme as we near the anticipated commercial launch of arimoclomol, if approved, in its first indication and as we look forward to data readouts from pivotal stage clinical trials testing arimoclomol in ALS and sporadic Inclusion Body Myositis (sIBM) during H1 2021.”

    https://finance.yahoo.com/news/orphazyme-announces-interim-report-first-050000747.html
  • G
    Greenberg
    of course this low float stock is a MEGA buying opp at $19 million valuation which is close to their cash balance of $14.6 million or Cash for 3 Years . There is some dumping on smaller biotech stocks in last days and this hurts CYTR as well . There a big milestones coming within next 6 months including potential FDA approval of Arimiclomol (Orphan Drug) which means milestones payment and royalties to CYTR this could push the company into profitability .
  • G
    Greenberg
    (CYTR-DD) Market Cap $22 M -Cash $14.6 M or Cash for 3 Years / Shares Out 33.6 M / 1 Orphan Drug with potential FDA approval in Q1 / 3 x Phase 3 Programs including 2 potential Blockbusters / has 2 BIG Orphan and Cancer Drug Pipeline / CYTRX has Drug deals worth $460 Million (see presentation below) = One of the MOST cheapest bio gem out there with MASSIV upside potential also a attractive takeover target at this low price .

    Upcoming Milestones
    https://assets.wallstreet-online.de/_media/8763/board/20200820135813-screenshot-2020-08-20-cytr-corp-overview-q3-2020-.png

    Orphan Drug Pipeline
    https://assets.wallstreet-online.de/_media/8763/board/20200820135838-screenshot-2020-08-20-cytr-corp-overview-q3-2020-.png

    Cancer Pipeline
    https://assets.wallstreet-online.de/_media/8763/board/20200820142025-screenshot-2020-08-20-cytr-corp-overview-q3-2020-.png

    New Presentation
    http://www.cytrx.com/wp-content/uploads/2020/08/CYTR-Corp-Overview-Q3-2020-Non-Conf.pdf
  • P
    Purgatory
    Anyone attending the meeting. I am sure Kriegsman will require the usual invitation only admittance and no questions! There will be however be a bowl of Doritos(1 bag limit). Throw a pie for me when you see him and ask if he plans to give his 15% net profit from future milestone payments to his fav charity?
  • K
    Knownow
    Back of napkin estimate...Upon approval for NPC, 2020 H2, SP to jump to $.75. - 1.11. Cash on hand will move to approx. $20M = $6M US milestone payment plus $13M present cash on hand. No buyout possible until 2021 H2 with data readouts. If US compassionate use granted for ALS or sIBM, SP could go to $5 in 2021,H1.
    All speculation of course and subject to SK shenanigans.
  • K
    Knownow
    Just two what if"s:

    What if FDA grants early compassionate use?
    What if Orphazyme offers a buyout?
  • C
    CoolCarlos
    Looks like we have a GEM in place now! This is guaranteed money for the best that know how to navigate through these financial markets
  • G
    Green
    This one is a hidden gem
  • L
    L
    This is a money laundering scam. I’m surprised fed didn’t show up at Kreigsman door yet.
  • G
    Greenberg
    Could break $1 anytime now ..LOTS of big milestones on the way like BLA Acceptance by FDA for Arimiclomol (NPC Drug ) , MAA submission for European approval expected during next 2-3 months and FDA Decision in early Q1 2021 . Market Cap of 23 million is more than just a PURE GIFT ...STRONG BUY
    https://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=61175282&Type=Custom&Intraday=1&Width=336&Height=360&Cycle=NONE&Duration=4&Render=Candle&ShowCopyright=2&ShowName=0&Company=4Traders_de
  • G
    Greenberg
    At this very low valuation of 21 million CYTR is a GREAT takeover candidate for both of their partner (Immunitybio & Orphazyme )
    https://assets.wallstreet-online.de/_media/8763/board/20200824202937-screenshot-2020-08-24-cytr-corp-overview-q3-2020-.png
  • W
    Wgozep
    Accumulation going on. Buy rating: 6, target: 0.97, according to 9trading.
  • L
    L
    Where is greenberg now ?
  • G
    Greenberg
    Added 15k shares thank you im happy to get the shares ahead of BLA acceptance expected next month .